Jean Pierre Evenou

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation
    Jean Pierre Evenou
    Novartis Institute for Biomedical Research, WSJ 386 5 27, CH 4002 Basel, Switzerland
    J Pharmacol Exp Ther 330:792-801. 2009

Detail Information

Publications1

  1. ncbi The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation
    Jean Pierre Evenou
    Novartis Institute for Biomedical Research, WSJ 386 5 27, CH 4002 Basel, Switzerland
    J Pharmacol Exp Ther 330:792-801. 2009
    ..The mode of action of AEB071 is different from that of calcineurin inhibitors, and AEB071 and cyclosporine A seem to have complementary effects on T-cell signaling pathways...